Connecticut is currently home to 1256 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Brain-Training Treatment for Long COVID in Older Adults
NCT05705193
Recruiting
This research is being done to collect preliminary data on the potential of computerized "brain-training" exercises for treating Long COVID symptoms in older adults. The investigators hypothesize that computerized brain-training will be an acceptable and feasible intervention for treating Long COVID symptoms in older adults. The investigators also expect to provide initial evidence that computerized brain-training has potential for improving thinking, mood, and other aspects of everyday function... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/25/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Post-Acute COVID-19 Syndrome
Register for Updates
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05629208
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Yale Center for Clinical Investigation (YCCI), New Haven, Connecticut
Conditions: Cutaneous Lupus Erythematosus (CLE)
Register for Updates
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
NCT05576350
Recruiting
Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit "ri... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Risk Behavior, Alcohol Use Disorder, HIV Infections
Register for Updates
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
NCT05669534
Recruiting
The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: APT Foundation, New Haven, Connecticut
Conditions: Hiv, Opioid Use Disorder
Register for Updates
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922
Recruiting
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors
Register for Updates
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Stroke, PFO - Patent Foramen Ovale
Register for Updates
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727
Recruiting
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/22/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Glycogen Storage Disease
Register for Updates
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
NCT06821750
Recruiting
The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/20/2025
Locations: Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Conditions: Healthy
Register for Updates
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
NCT05098132
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Yale New Haven Hospital, Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Register for Updates
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT04792502
Recruiting
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
Register for Updates
Social Disconnection Study
NCT06705348
Recruiting
The purpose of this research study is to examine the effect of social connectedness on the brain. Study procedures include one Magnetic Resonance Imaging (MRI) or functional Magnetic Resonance Imaging (fMRI) scan, one Positron Emission Tomography (PET) scan, one Magnetic Resonance Spectroscopy (MRS) scan, an electroencephalogram (EEG), and in-person and phone call follow-ups.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/18/2025
Locations: Yale Translational Brain Imaging Program, New Haven, Connecticut
Conditions: Social Disconnection
Register for Updates